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Main points: 
- Astrocytes expressing mutant Huntingtin are key contributing actors to 
behavioural phenotype and cellular alterations 
- Alterations of glial glutamate metabolism are caused by astrocyte-specific and 
neuron-specific expression of mutant Huntingtin 5 
Key words:  
Glia; Polyglutamine expansion; Adeno-associated viral vectors; Striatum; Mouse model 
 
Page 2 of 52
John Wiley & Sons, Inc.
GLIA
3 
 
 
Abstract 
Huntington’s disease (HD) is a fatal neurodegenerative disease in which an early and selective 
vulnerability of striatal Spiny Projection Neurons is observed. However, several studies have 
highlighted the implication of glial cells, and in particular astrocytes, in the pathophysiological 5 
mechanisms of this disease. A better understanding of the respective contributions of neurons 
and astrocytes in HD is needed and would be important for the development of new therapeutic 
approaches. Today, no comparable in vivo models expressing the mutant HTT selectively in 
astrocytes or in neurons are available. In this study, we developed comparable cell-type specific 
mouse models expressing a fragment of Huntingtin specifically in neurons, astrocytes, or in both 10 
cell populations of the adult mouse basal ganglia circuit. These models allowed us to unravel 
some behavioural alterations occurring as soon as 4 weeks post-injection in the neuron-specific 
model, and additional dysfunctions when mHTT was co-expressed in astrocytes. We further 
evaluated the differential contribution of astrocytes compared to neurons in several 
pathophysiological mechanisms such as mHTT protein aggregation, astrogliosis and neuronal 15 
dysfunction. We observed that transcriptional alterations within the glial glutamatergic clearing 
system were caused both by both astrocytic and neuronal expression of mHTT. We anticipate 
that our study will help to better understand the contributions of astrocytes to HD and guide 
future therapeutic efforts. 
20 
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Introduction 
Huntington’s disease (HD) is a rare neurodegenerative disease affecting around 5-7 per 
100.000 people worldwide. The pathology is caused by an autosomal dominant genetic mutation 
located on the IT15 gene (Huntingtin gene, HTT), coding for the Huntingtin protein (HTT; (The 5 
Huntington's Disease Collaborative Research Group 1993). CAG repeats within the Exon 1 ≥ 40 
cause the formation of a toxic polyglutamine stretch at the N-terminal part of the protein. Patients 
develop progressive motor, cognitive, psychiatric and physiological alterations starting between 
age 35 and 50  leading to death within 15-20 years (Roos 2010). HD pathophysiology is marked 
by an early degeneration of the Spiny Projection Neurons (SPNs) of the striatum, which 10 
represent more than 90% of the striatal neurons. The abnormal polyglutamine stretch on HTT 
leads to a toxic gain of function of the protein, resulting in a pathological accumulation of HTT 
aggregates with cellular and transcriptional alterations (Zuccato et al. 2010). Up to now, the 
vulnerability of SPNs is not completely understood. HTT is ubiquitously expressed in the brain 
and in peripheral tissues, and differences in HTT expression levels are not sufficient to explain 15 
this preferential vulnerability (Fusco et al. 1999).  
During the last decades, numerous studies demonstrated the essential role of astrocytes 
in key biological functions (Chung et al. 2015). Surprisingly, only few pathophysiological 
alterations linked to glial cells have been described in HD patients and animal models. A 
progressive astrogliosis has been observed in the post-mortem brain of HD patients and animal 20 
models, together with alterations of the glutamate-glutamine cycle and of ascorbic acid 
metabolism (Acuna et al. 2013; Faideau et al. 2010). Mouse models expressing mutant HTT 
(mHTT) specifically in astrocytes have been previously developed to confirm the implication of 
these cells in HD (Bradford et al. 2009; Faideau et al. 2010). However, the small-transduced 
area obtained with lentiviral vectors has limited the evaluation of the contribution of astrocytes to 25 
the behavioral phenotype. Importantly, the differences in terms of HTT constructions and CAG 
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repeats number make the comparison of transgenic models expressing mHTT in neurons or in 
astrocytes difficult. 
Viral vectors such as Adeno-Associated Viruses (AAV) are potent tools to express a 
transgene in the central nervous system. The modulation of AAV capsids together with cell-type 
specific promoters have opened the possibility to shift the expression of a transgene from one 5 
cell population to another (Merienne et al. 2013). Furthermore, AAV vectors have been already 
used to efficiently express mHTT in the mouse brain (Franich et al. 2008; Hult et al. 2011). In 
this study, we took advantage of AAV properties and specific promoters to develop mouse 
models in which mHTT is selectively expressed in neurons or in astrocytes of the basal ganglia 
system, with a stable and similar expression rate. Additionally, we obtained a parallel expression 10 
of mHTT in both cell populations by co-injecting the two cell-type specific AAVs. With these 
models, we were able to evaluate behavioral, cellular and molecular dysfunctions as soon as 4 
weeks post-injection. This study highlights the respective contributions and vulnerabilities of 
neurons and astrocytes in Huntington’s disease, and an indirect but essential role of glial cells in 
the pathophysiological mechanisms. It also opens the possibility to apply a similar approach to 15 
study the individual contribution of distinct cell types, including different glial cell types, in other 
neurodegenerative diseases. 
Materials and methods 
The complete Experimental Procedures section can be found as online Supplemental 
Experimental Procedure. 20 
Animals 
All animal procedures were approved by the Swiss “Service de la Consommation et des Affaires 
Vétérinaires” (SCAV, authorization n°2747.0, see Supplemental Experimental Procedures). 
Injections 
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All mice were injected at 11 weeks old. Injections parameters, doses and surgical procedures 
can be found in Supplemental Experimental Procedure.  
Behavioral tests 
Living conditions such as testing time, room and light were kept identical between groups. Order 
of mice was balanced between HTT171-82Q and HTT171-18Q groups. Investigator was the 5 
same for all tests and between all groups, and behavioral tests started one week before 
euthanasia (see Supplemental Experimental Procedure). 
Brain samples processing 
After lethal injection of Pentobarbital solution (150mg/kg), mice were either quickly decapitated 
to further extract mRNA and proteins of striatal eGFP-positive punches with TRIzol Reagent ® 10 
(see Suplemental Experimental Procedures), or fixed by intra-cardiac perfusion of Sodium-
Phosphate buffer (0.4M) with Paraformaldehyde 4% for immunohistochemical analysis (see 
Supplemental Experimental Procedure).  
Immunohistochemistry 
20µm free-floating coronal brain sections were used in this study. Primary and secondary 15 
antibodies are described in Supplemental Experimental Procedures. For image acquisition, 
except when mentioned in figure legend, identical parameters were maintained between all 
groups, and quantification analyses were performed on raw, unmodified pictures. ImageJ 1.44p 
software was used for all analyses (See Supplemental Experimental Procedure).  
RT-qPCR 20 
After mRNA extraction, DNAse treatment and random-primed first strand complementary DNA 
(cDNA) synthesis were performed on samples (see Supplemental Experimental Procedures). 
Real-Time quantitative PCR was performed with StepOne Real Time PCR System 
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(ThermoFisher Scientific). Detailed primer sequences and protocols are available in 
Supplemental Experimental Procedures.  
Western blot 
After protein extraction, proteins from each sample were loaded on polyacrylamide gel for further 
immunoblot analysis (see Supplemental Experimental Procedures). Groups were equally 5 
represented on each membrane to allow further comparisons. Details about antibodies and 
analysis are described in Supplemental Experimental Procedures.  
Statistical analysis 
Data were analyzed using Statistica 10 Statsoft software. Student’s t test, Factorial ANOVA or 
Repeated-measures ANOVA were performed, followed by post hoc LSD Fisher analysis. P 10 
value <0.05 was considered as significant. Data are expressed as mean ± SEM (see 
Supplemental Experimental Procedure). 
Results 
AAV2/5 with distinct promoters leads to cell-type specific expression of mHTT in the adult mouse 
striatum  15 
In order to obtain cell-type specific transgene expression in the mouse striatum, Adeno-
Associated Viral vectors 2/5 (AAV2/5) containing either the Chicken-β Actin promoter (CBA) or a 
truncated form of the Glial Fibrillary Acidic Protein promoter including three enhancers (de 
Leeuw et al. 2006) were developed. AAV2/5 expressing the enhanced green fluorescent protein 
(eGFP) under the CBA or Gfa2(B)3 promoter (CBA-eGFP or Gfa2(B)3-eGFP) was injected in 20 
the striatum of adult mice to evaluate their respective tropism (Figure 1A). Confocal microscopy 
analysis revealed that more than 90% of cells transduced with CBA-eGFP were NeuN-positive, 
whereas more than 90% of cells transduced with Gfa2(B)3-eGFP were positive for Glutamine 
Synthetase (GS, Figure 1B), confirming a specific transduction of neurons or astrocytes, 
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respectively. Furthermore, we qualitatively observed that the AAV2/5 transduces a large area of 
the mouse striatum, both in the antero-posterior and medio-lateral axes (Supplemental Figure 
S1A). We evaluated the ability of AAVs vectors to transduce other structures of the basal ganglia 
circuit by co-injecting an AAV2/5 expressing mCherry under the CBA promoter and an AAV2/5 
expressing eGFP under the Gfa2(B)3 promoter in the striatum. Both eGFP- and mCherry-5 
positives cells were detected in the pallidum, nucleus accumbens, substantia nigra and in the 
primary motor cortex (Supplemental Figure S1B). In summary, the two AAV2/5 viral vectors 
differing only by their respective promoter represent efficient tools to specifically express a 
transgene in neurons or in astrocytes, in the adult mouse striatum and in part of the basal 
ganglia circuit.  10 
 The cell-type specific expression of mHTT was next obtained by cloning a sequence 
coding for the first 171 amino acids of the human HTT protein under the control of either the 
CBA or Gfa2(B)3 promoter. The mHTT contained 82 CAG repeats (HTT171-82Q), whereas the 
control HTT contained only 18 CAG repeats (HTT171-18Q-HA, (de Almeida et al. 2002). AAV2/5 
viral vectors expressing the mutant or the control HTT under the CBA or the Gfa2(B)3 promoter 15 
were injected in the striatum at low dose (5E107 viral genome/site), thus allowing a specific 
expression of control or mutant HTT in neurons or in astrocytes and a progressive appearance 
of the pathology (CBA-HTT171-82Q, CBA-HTT171-18Q, Gfa2(B)3-HTT171-82Q or Gfa2(B)3-
HTT171-18Q mice, Figure 1C). Additionally, to obtain HTT expression in both cell populations at 
once, co-injection of neuron-specific and astrocyte-specific viral vectors was performed 20 
(CBA/Gfa2(B)3-HTT171-82Q or CBA/Gfa2(B)3-HTT171-18Q mice, 5E107 viral genome/site per 
viral vector, Figure 1C). Visualization of the transduced area and validation of the injection 
accuracy were performed by co-injecting in each mouse either the CBA-eGFP or the Gfa2(B)3-
eGFP viral vector at very low dose (4E106 viral genome/site). Reverse-Transcription Quantitative 
Polymerase Chain Reaction (RT-qPCR) with primers recognizing both the murine and human 25 
Page 8 of 52
John Wiley & Sons, Inc.
GLIA
9 
 
HTT mRNA confirmed mHTT expression levels approximately 13 fold higher than the 
endogenous Htt level in non-injected mice for the neuronal and the astrocytic model from 4 to 16 
wpi (Figure 1D). The co-injection of both CBA-HTT171-82Q and Gfa2(B)3-HTT171-82Q AAV2/5 
led to an expression level of mHTT approximatively 42 fold higher than the level of endogenous 
Htt from 4 to 16 wpi. A statistical analysis confirmed a similar expression between the neuronal 5 
and the astrocytic model, a significant increase in CBA/Gfa2(B)3-HTT171-82Q mice (double 
model) and a stable expression of the transgene from 4 to 16 wpi in each group. Altogether, 
optimization of promoters and injection parameters with AAV2/5 enable a high, stable and 
similar expression of mHTT between neurons and astrocytes in vivo. 
Co-expression of mHTT in neurons and in astrocytes does not exacerbate behavioral deficits 10 
induced by neuronal mHTT but caused additional alterations.  
 HD patients develop motor, psychiatric, and cognitive symptoms. Thus, the phenotype of 
the three mouse models was characterized by measuring anxiety, spontaneous motor activity, 
locomotor coordination and the presence of abnormal movements.  
Thigmotaxic behavior during an Open Field task corresponds to the tendency of a mouse 15 
to travel closer to the walls and less in the arena center, which is a recognized marker of anxiety 
in HD mouse models (Pla et al. 2014). Here, mice expressing mHTT specifically in neurons or in 
both neurons and astrocytes travel significantly more in the external field compared to control 
mice, from 4wpi to 12 wpi (Figure 2A). This suggests an increased anxiety in these two models. 
No significant thigmotaxic behavior was observed in mice expressing mHTT only in astrocytes. 20 
Analysis of the total distance traveled in the Open Field did not reveal spontaneous motor 
activity alterations in mice expressing mHTT only in neurons or in astrocytes, but a significant 
hyperactivity appeared from 12 wpi to 16 wpi in the group with mHTT co-expressed in both cell 
types (Figure 2B).  
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Locomotor coordination in a forced motor task was evaluated with the Rotarod 
Accelerated Test. The expression of mHTT only in neurons induced a significant deficit in 
locomotor coordination at 12 wpi and 16 wpi, and a deficit at 8 and 16 wpi when mHTT is 
expressed in both cell types (Figure 2C). In contrast, mHTT expression restricted to astrocytes 
only led to a mild locomotor alteration in this test at 16 wpi (Figure 2C). Then abnormal 5 
movements such as clasping were evaluated in each mouse model. Only the co-expression of 
mHTT in both neurons and astrocytes was able to significantly induce the appearance of 
clasping behavior starting at 8 wpi (Figure 2D). Finally, physiological alterations such as weight 
loss have also been described in HD patients (van der Burg et al. 2009). However, whether 
these alterations are the consequence of mHTT expression in the brain or in peripheral organs 10 
is still unclear. Here, the weight gain in each model following the surgery up to euthanasia was 
determined. A significant decrease in weight gain was observed in mice expressing mHTT only 
in neurons at 16 wpi and in mice expressing mHTT in neurons and in astrocytes at the same 
time, but not when the expression was restricted to astrocytes (Figure 2E). 
Altogether, these results demonstrate that expression of mHTT restricted to neurons of 15 
the basal ganglia circuit is sufficient to induce significant behavioral and physiological 
alterations, whereas its expression only in astrocytes only induces mild locomotor deficits.. 
Furthermore, the co-expression of mHTT both in neurons and in astrocytes did not exacerbate 
deficits observed in the neuron-specific model but additionally induced hyperactivity and 
clasping.  20 
Striatal neurons and astrocytes exhibit distinct mHTT aggregation patterns 
 Considering the different behavioral phenotypes observed between the three mouse 
models, the histopathological consequences of mHTT expression in striatal cells was 
investigated. Specific immunolabelings for aggregated mHTT revealed the aggregation of the 
protein in the three mouse models as soon as 4 wpi (Figure 3A), whereas no detectable mHTT 25 
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aggregates were observed in any of the control groups (Supplemental Figure S2A). No sign of 
aggregates spreading from one cell population to another was observed in the two cell-type 
specific models (Supplemental Figure S2B). Consistent with the presence of eGFP- or mCherry-
positive cells in other structures, mHTT aggregates were observed in the lateral globus pallidus, 
the nucleus accumbens and the cortex, in both CBA-HTT171-82Q and Gfa2(B)3-HTT171-82Q 5 
mice (Supplemental Figure S3A). mHTT aggregates were also observed in the substantia nigra 
pars compacta, except in the astrocytic model. No aggregates were observed in the arcuate 
nucleus of the hypothalamus (Supplemental Figure S3B).  
Interestingly, quantifications confirmed the presence of a higher number of aggregates at 
16 wpi when mHTT was expressed in neurons compared to astrocytes (Figure 3B). The co-10 
expression of mHTT in neurons and in astrocytes led to a higher number of aggregates 
compared to the two cell-type specific models at 16 wpi (Figure 3B). A previous study 
distinguished large mHTT aggregates with a diameter >3µm and small HTT inclusions with a 
diameter <3µm (Sahl et al. 2012). Using this criteria, quantifications indicated a higher proportion 
of large aggregates in neurons compared to small aggregates, whereas the opposite pattern 15 
was observed in astrocytes (Figure 3C). Furthermore, high magnification confocal imaging 
revealed large aggregates in nuclear or cytoplasmic compartments whereas small aggregates 
could be located in nuclear, cytoplasmic or dendritic/process compartments (Figure 3D). 
Considering these results, it became clear that mHTT in striatal neurons and in astrocytes 
undergoes aggregation or clearing processes specific for each cell population. 20 
mHTT expression in astrocytes exacerbates early dysfunction of striatal SPNs 
 Dysfunction of the striatal SPNs is closely linked to the phenotype of HD mouse models 
and to deficits observed in HD patients (Guo et al. 2012). Here, the protein and mRNA levels of 
Dopamine- and cAMP-Regulated PhosphoProtein, 32kDa (DARPP-32, Ppp1r1b), a typical 
marker of functional SPNs, were determined. An histological analysis revealed a decrease of 25 
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DARPP-32 staining intensity in the striatum of CBA-HTT171-82Q mice, starting at 8 wpi, 
whereas no DARPP-32 lesion was observed in Gfa2(B)3-HTT171-82Q mice, compared to 
control mice (Figure 4A-B). The DARPP-32 lesion was exacerbated when mHTT was co-
expressed in both cell populations, and detectable as early as 4 wpi (Figure 4A-B). These results 
were confirmed at the mRNA level by RT-qPCR, showing a significant decrease (53.8%) of 5 
Ppp1r1b expression in CBA-HTT171-82Q mice from 8 wpi to 16 wpi (Figure 4C). The co-
expression of mHTT both in neurons and astrocytes exacerbated this dysfunction by inducing a 
66.4% decrease of Ppp1r1b expression from 4 wpi to 16 wpi. We confirmed the absence of 
neuronal death in all groups by NeuN immunolabeling (Supplemental Figure S4).  
 Here, intrinsic neuronal alterations caused by mHTT appears to be sufficient to trigger 10 
early dysfunction of SPNs in HD. However, even if mHTT expression restricted to astrocytes is 
not sufficient to induce alterations in non-transduced SPNs, astrocytes expressing mHTT 
contribute to accelerate the pathology.  
Co-expression of mHTT in neurons and astrocytes induces early signs of astrogliosis  
A progressive astrogliosis was previously described in HD patients and in animal models 15 
(Faideau et al. 2010). The origin and contribution of this pathophysiological mechanism to the 
development of the disease are still poorly described. In this context, it was interesting to 
determine if the neuronal expression of mHTT was sufficient to trigger astrocytic modifications 
such as astrogliosis.  
A first analysis of total Gfap mRNA levels shown no difference between groups 20 
expressing mHTT and control groups in the three different mouse models (Figure 5A). In a 
second step, Gfap protein level was evaluated using immunohistochemistry by measuring the 
integrated density of labeling in striatal Gfap-positive astrocytes. A significant increase in was 
observed at 16 wpi when mHTT was co-expressed in both neurons and astrocytes, but not when 
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mHTT was only expressed in neurons or in astrocytes (Figure 5B). Furthermore, the evaluation 
of a putative hypertrophic morphology of striatal astrocytes indicated an increase total Gfap-
positive area only in mice expressing mHTT in both neurons and astrocytes (Figure 5C-D). 
Interestingly, these results can not be explained by the total number of Gfap-positive cells 
(Supplementary Figure 5B). In addition, no difference was observed at 4wpi between the three 5 
models as well as between mutant and control groups, indicating that this result was not a mere 
consequence of the injection (Supplementary Figure 5A). Our data suggest that at these stages 
mHTT only in astrocytes is not sufficient to trigger astrogliosis, and that a concomitant neuronal 
dysfunction seems to be required to observe a glial reactivity. 
Transcriptional alterations of the glutamate-glutamine cycle in HD are caused by both neuronal 10 
and astrocytic mHTT expression 
 In HD, glutamatergic excitotoxicity is a major contributor of neuronal degeneration 
(Estrada Sanchez et al. 2008). Glutamate-induced toxicity can be caused by a dysfunction of 
glutamate clearing by astrocytes and by alterations of neuronal N-methyl-D-Aspartate receptors 
(NMDAR), including transcriptional dysfunctions (Zuccato et al. 2010).  15 
An analysis of the glutamate recycling process in the three mouse models was carried 
out by evaluating mRNA levels of the two glutamate transporters Excitatory Amino Acid 
Transporters 1 and 2 (Glast, Slc1a3 and Glt1, Slc1a2). In addition, mRNA levels of the α2 
subunit of the Na+/K+-ATPase (Atp1a2), which is a crucial actor in ion exchanges needed for the 
maintenance of glutamate transporter activity, were determined, together with Glutamine 20 
Synthetase (Gs, Glul), which is the key enzyme for the astrocytic glutamate conversion to 
glutamine. RT-qPCR showed that the expression of mHTT in astrocytes leads to a significant 
decrease of Slc1a2 (Glt1) and Slc1a3 (Glast) mRNA levels, starting at 12 wpi and 8 wpi 
respectively (Figure 6A-B). In this model, Atp1a2 and Glul (Gs) mRNA significantly decreased at 
12 and 4 wpi respectively (Figure 6C-D). Interestingly, mHTT in neurons also led to a significant 25 
decrease of these four components of the astrocytic glutamate clearing process (Figure 6A-D). 
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Finally, the co-expression of mHTT in the two cell populations strongly exacerbated these 
transcriptional alterations for Slc1a2, Slc1a3, Atp1a2 and Glul (Figure 6A-D). Western blot 
analysis confirmed a significant decrease of Glt1 protein levels only in but the double model 
(Figure 6E).  
In parallel, mRNA levels of two major subunits of the NMDA receptor (NMDAR) were 5 
analyzed: NR1 (Grin1) which is not mainly affected by mHTT, and Nr2b (Grin2b) which is highly 
associated with glutamatergic excitotoxicity (Ali and Levine 2006). Results showed no alteration 
of Grin1 expression levels in any of the three models, except for a mild but significant decrease 
at 12 wpi in CBA-HTT171-82Q mice (Figure 6F). On the other hand, the neuron-specific 
expression of mHTT was sufficient to induce a significant decrease of Grin2b mRNA levels at 8, 10 
12 and 16 wpi, whereas this decrease was not significant when mHTT was expressed in both 
neurons and in astrocytes, except at 16 wpi (Figure 6G). No such alteration was found in the 
astrocyte-specific mouse model (Figure 6G). In summary, it was found that both neuron- and 
astrocyte-specific mHTT expression lead to alteration of various astrocytic components of the 
glutamate recycling process at the transcriptional level. In contrast, only mHTT expressed in 15 
neurons is able to alter the expression of the Nr2b subunit.  
DARPP-32 and key elements of the Glutamate-glutamine cycle are closely linked to locomotor 
performances 
In this study several pathophysiological hallmarks of HD and their evolution in three distinct 
models have been described. In order to analyze a putative link between transcriptional deficits 20 
and behavioral alterations, we performed Pearson correlation analysis on the expression levels 
of key elements involved in HD pathophysiology (Ppp1rb, Gfap) as well as in the Glutamate-
Glutamine cycle (Slc1a2, Slc1a3, Atp1a2, Glul, Grin1, Grin2b), and on behavioral performances 
of mice. This analysis was ran on all time points, both in HTT171-18Q and HTT171-82Q mice, 
separately in the three models. A p value reflecting the probability of true correlation was 25 
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calculated for each Pearson correlation and corrected for multiple testing according to the 
Benjamini and Hochberg method (Benjamini and Hochberg 1995).  
This analysis showed distinct correlation patterns between each model. In CBA-HTT171 
mice, we showed significant positive correlations between genes involved in the Glutamate-
Glutamine cycle (Glt1, Glast, Atp1a2, GS, Figure 7A). Interestingly, this cluster also includes 5 
DARPP-32, which positively correlates with all these genes and in particular Glt1 (r = 0.93, 
FDR<0.0001). In the astrocytic model, we only observed positive correlations between the 
Glutamate-Glutamine cycle elements but not with DARPP-32, except for Glt1 (Figure 7B). 
Finally, in mice expressing mHTT in neurons and in astrocytes, the cluster which brings together 
Glutamate-Glutamine cycle genes and DARPP-32 is present (Figure 7C). Interestingly, in this 10 
more severe pathological context, significant positive correlations are observed between 
behavioral performances, mRNA levels of DARPP-32 and elements of the Glutamate-Glutamine 
cycle (Figure 7C). These results suggest an important link between expression levels of DARPP-
32 and glutamate recycling, in particular Glt1, that are also related to behavioral performance 
such as motor coordination, locomotion and abnormal clasping.  15 
 
Discussion 
In this study, we developed three cell-type specific mouse models of HD in order to analyze 
the respective contributions of neurons and astrocytes to the pathophysiology of the disease. 
AAV2/5 expressing mHTT under CBA or Gfa2(B)3 promoters allowed us to obtain high, stable 20 
and similar expression levels of mHTT in neurons and in astrocytes of part of the basal ganglia 
circuit, and to co-express mHTT in both cell populations. All models exhibited typical behavioral, 
cellular and molecular dysfunctions of HD, but their evolution and severity differed (Figure 8A-C).  
Expression of mHTT in basal ganglia neurons is sufficient to affect body weight 
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The significant decreased weight gain observed at 16 wpi in models expressing mHTT in 
neurons or in both neurons and astrocytes was an unexpected result. A progressive body weight 
loss is observed in the late stages in HD patients, but only reproduced in transgenic mouse 
models with ubiquitous expression of a short HTT fragment (Phan et al. 2009). In contrast, 
transgenic mice expressing full-length HTT demonstrate increased body weight (Van 5 
Raamsdonk et al. 2006). Interestingly, the specific expression of a long or a short fragment of 
mHTT in the hypothalamus induced increased body weight in mice (Hult et al. 2011). These 
studies highlighted the role of hypothalamic dysfunctions in metabolic alterations observed in 
some mouse models, but also suggested that the body weight loss observed in patients at late 
stages of the disease and in short fragment mouse models would be mainly due to mHTT effects 10 
on peripheral organs and tissues (Carroll et al. 2015). 
In our study we showed that the expression of a short fragment in part of the basal ganglia 
circuit is sufficient to explain at least part of the metabolic dysfunction linked to body weight loss. 
Importantly, AAV2/5 used in this study transduced the nucleus accumbens (NAcc), in which we 
observed mHTT-positive aggregates. The NAcc and the striatum are key components of the 15 
meso-limbic dopaminergic system that directly interact with the ventral tegmental area and the 
lateral hypothalamus to regulate the motivational and rewarding aspects of food intake (Wise 
2006). In this context, dysfunctional SPNs could potentially alter the balance between the 
hypothalamus and the rewarding system. In future studies, it would be interesting to investigate 
the effect of mHTT in the hypothalamus or in the basal ganglia circuit specifically on food intake 20 
regulation. 
Distinct mHTT aggregation and/or clearing processes are observed in neurons and astrocytes 
An early aggregation of mHTT is observed in the three mouse models as soon as 4 wpi, 
which is characteristic of models expressing short mHTT fragment (de Almeida et al. 2002). 
Additionally, we observed fewer numbers of aggregates in astrocytes compared to neurons, and 25 
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the majority of detected aggregates in astrocytes had a diameter < 3 µm. This suggests that glial 
cells possess distinct mechanisms of cleavage and/or clearing of mHTT compared to neurons. 
We expressed only the first 171 amino acids of HTT, excluding most putative cleavage sites by 
caspases or calpains located after the first 200 amino acids (Zuccato et al. 2010). However, a 
previous study described a Cp-2 cleavage site for cysteine proteases, located at the position 5 
Arg167 and acting both on mHTT toxicity and on the aggregation process (Ratovitski et al. 2009). 
One plausible hypothesis is that cell-type specific expression or regulation of cysteine proteases 
between neurons and astrocytes could explain the differential aggregation processes.  
Clearing of mHTT aggregates in the nucleus and in the cytoplasm depends on the Ubiquitin-
Proteasome system, which was shown to have a higher activity in glial cells compared to 10 
neurons, leading to higher efficiency for the degradation of misfolded protein (Tydlacka et al. 
2008). Previous studies demonstrated that an increased proteasome activity could lead to a 
higher number of small inclusions compared to diffuse forms (Venkatraman et al. 2004), which is 
consistent with the pattern observed here in astrocytes. Small HTT inclusions were also 
associated with a higher toxicity, whereas large inclusions or diffuse aggregates could be linked 15 
to a protective mechanism by the cell (Arrasate et al. 2004). Neurons being the most affected by 
mHTT, it may appear contradictory that astrocytes present mainly the most toxic form of mHTT 
aggregates and neuronal cells the most protective one. Neuronal cells having a lower 
proteasome activity, they could potentially compensate the higher total number of aggregated 
mHTT by a protective mechanism leading to the formation of large and diffuse aggregates 20 
concomitantly with small inclusions. In contrast, a higher proteasomal activity combined with 
specific cleavage mechanisms in astrocytes could explain a fewer total number of aggregates 
with a higher proportion of small inclusions that could not be degraded by the proteasome. 
mHTT in neurons affects mRNA levels of key elements of the glial glutamate-glutamine cycle 
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Despite the smaller number of mHTT aggregates observed in astrocytes, we found that glial 
cells are affected at the transcriptional level with a significant decrease of GLT1, GLAST, GS 
and Na+/K+-ATPase α2 subunit mRNA levels. These results are highly consistent with previous 
studies on HD patients and animal models (Estrada Sanchez et al. 2008). Furthermore, no 
behavioral or neuronal alterations were induced by mHTT in astrocytes, suggesting an ability of 5 
glial cells to compensate at least partially these down-regulations to maintain a sufficient 
glutamatergic recycling activity for surrounding cells to prevent neuronal dysfunction. 
We observed a decreased mRNA expression of the two main glutamate transporters GLT1 
and GLAST, as well as of glutamine synthetase and the α2 subunit of the Na
+/K+-ATPase when 
mHTT was expressed only in neurons. In a previous study, neuron-specific expression of mHTT 10 
by injection of a lentiviral vector did not lead to a decrease of GLT1 or GLAST expression at the 
protein level, which is coherent with our present results. However the mRNA levels of these two 
transporters were not investigated (Faideau et al. 2010). Glt1, Glast, Gs or Atp1a2 being mainly 
expressed by astrocytes, our results suggest that a neuronal dysfunction could indirectly affect 
astrocytic glutamate recycling components at the transcriptional level in a positive or negative 15 
manner. In vitro experiments on primary cultures of astrocytes suggested that soluble factors 
could be released by neurons and act via a kappa B-motif binding protein (KBBP) to increase 
GLT1 mRNA levels (Yang et al., 2009). Other studies highlighted the role of endothelins as 
regulators of GLT1 expression and activity, especially in a pathological context (Glisic et al., 
2012).. To our knowledge, an indirect contribution of mHTT in neurons to transcriptional 20 
alterations of glutamate recycling components in astrocytes was not shown in previous studies, 
and which pathways and factors are involved in this mechanism remain to be determined. 
Relationship between locomotor activity, DARPP-32 expression and glutamate clearing 
Interestingly, in the double model we observed a significant correlation between DARPP-32 
mRNA and behavioral deficits in locomotor coordination, spontaneous motor activity and 25 
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clasping. Furthermore, correlation analysis also showed a significant link between DARPP-32 
and Glt1 mRNA levels. In the striatum, the DARPP-32 protein acts as a pivotal element to 
modulate activity and responses of SPNs as a consequence of multiple signal integration 
(Greengard et al. 1999). DARPP-32 phosphorylation and activity are mainly regulated by 
dopaminergic inputs, but are also linked to glutamatergic neurotransmission (Blank et al. 1997). 5 
However, to our knowledge, a link between DARPP-32 and glutamate clearing by astrocytes at 
the mRNA level has never been shown. Future studies aiming at understanding how expression 
of DARPP-32 and astrocytic glutamate transporters such as Glt1 are concomitantly modulated 
will bring important new insights in the regulation of glutamatergic inputs on SPNs. 
Perspectives  10 
Currently, no treatment is available for HD patients. Several therapeutic strategies are 
considered, such as pharmacological approaches or gene therapy (Glorioso et al. 2015; Venuto 
et al. 2012). For gene therapy in neurodegenerative diseases, the question of targeting only 
neurons or additionally surrounding astrocytes still remains (Furman et al. 2012). Several 
approaches are available to directly target mHTT expression at the RNA level (small-hairpin 15 
RNA, shRNA) or at the DNA level (Clustered Regularly Interspaced Short Palindromic Repeats, 
CRISPR system; (Moore et al. 2010; Wright et al. 2016), and viral vectors were recently 
designed to express shRNA specifically in astrocytes (Merienne et al. 2015). These approaches 
will be important in the future to determine the necessity to treat both neurons and astrocytes in 
HD. Finally, recent major technological advances for single cell profiling were made (Heiman et 20 
al. 2008; Zhang et al. 2014). Their combination with cell-type specific expression of pathological 
transgenes will also be essential to precisely dissect the respective contribution of each brain 
cell population to neurodegenerative diseases, and to efficiently target key mechanisms acting 
on the whole cellular environment. Considering the high flexibility of viral vector approaches, we 
believe that the present study not only provides some interesting insights about the contribution 25 
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of astrocytes to the pathophysiology of HD, but also reveals the potential of such an approach 
for applications in the broader context of neurodegenerative diseases. 
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Figure legends 
Figure 1: Characterization of human HTT expression induced by cell-type specific AAV2/5  
(A) Representative confocal pictures of mouse striatum 3 weeks post injection of CBA-eGFP 
(upper panels) or Gfa2(B)3-eGFP AAV2/5 (lower panels). In CBA-eGFP mice, co-5 
immunolabeling with a neuronal marker (NeuN, Neuronal nuclei) was performed, whereas in 
Gfa2(B)3-eGFP a co-immunolabeling with Glutamine Synthetase (GS), a marker of astrocytes, 
was performed. Scale bar = 20µm. 
(B) Quantifications of the percentage of eGFP-positives cells that co-localized with NeuN or with 
GS, three weeks after injection of CBA-eGFP or Gfa2(B)3-eGFP AAV2/5 in mouse striatum. 10 
Data are presented as mean ± SEM, quantifications were performed on 4-6 pictures/section, 4 
sections/n, n= 4. 
 (C) AAV2/5 vectors allowed expression of either control HTT171-18Q-HA (blue cells) or mutant 
HTT171-82Q (red cells), in neurons (CBA), in astrocytes (Gfa2(B)3), or in both neurons and 
astrocytes (CBA/Gfa2(B)3), depending on the promoter. Forty mice/group were used in each 15 
experimental condition.. WPRE = Woodchuck Post-Regulatory Element, bGH = sequence of the 
polyadenylation signal of Bovine Growth Hormone gene. Gray boxes correspond to Inverted 
Terminal Repeats regions of AAV2. 
(D) RT-qPCR on total HTT (totHTT) was performed on striatum extracts from CBA-HTT171-82Q, 
Gfa2(B)3-HTT171-82Q and CBA/Gfa2(B)3-HTT171-82Q mice at 4, 8, 12 or 16 wpi, compared to 20 
non-injected mice (n=8-10/group, except for non-injected mice: n=5). Expression levels are 
normalized with Cyclophilin A levels (Ppia). Data represent mean ± SEM. *: p < 0.05, NS (Not 
Significant): p ≥ 0.05, Factorial ANOVA followed by LSD Fisher Post-Hoc tests, points represent 
individual samples. AU = Arbitrary Units, RE = Relative Expression. 
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Figure 2: Behavioral alterations after mHTT expression in neurons, in astrocytes or in both cell-
types. 
(A) Ratio of distance traveled in the external field/the total distance traveled by the HTT171-18Q 
mice (gray bars) or HTT171-82Q mice (black bars) during the Open Field task (n=9-10/group). 
Data represent mean ± SEM. *: p < 0.05, Factorial ANOVA followed by LSD Fisher Post-Hoc 5 
tests, points represent individual samples. 
(B) Total distance travelled was measured as an index of mouse spontaneous motor activity in 
the Open Field task (in meters, m, n=9-10/group). Data represent mean ± SEM. *: p < 0.05, 
Factorial ANOVA followed by LSD Fisher Post-Hoc tests, points represent individual samples. 
(C) Graphic representing latency to fall (in second, sec.) of mice during Rotarod Accelerated 10 
Test n=9-10/group). Data represent mean ± SEM of the three trials of each days. *: p < 0.05, 
Repeated-Measures ANOVA followed by LSD Fisher Post-Hoc tests. 
(D) Evaluation of clasping movements represented by the number of paw clasping (n=9-
10/groups). Data represent mean ± SEM. *: p < 0.05, Factorial ANOVA followed by LSD Fisher 
Post-Hoc tests, points represent individual samples. 15 
(E) Mouse body weight gain was evaluated between the surgery and euthanasia at 4, 8, 12 or 
16 wpi. Data are presented in grams (g), and represent mean ± SEM. *: p < 0.05, Factorial 
ANOVA followed by LSD Fisher Post-Hoc tests, points represent individual samples. 
Figure 3: mHTT aggregation patterns between striatal neurons and astrocytes  
(A) Representative pictures of immunohistochemical staining of mHTT aggregates with EM48 20 
antibody at 4, 8, 12 and 16 wpi, in the striatum of mice injected with CBA-HTT171-82Q (upper 
panels), Gfa2(B)3-HTT171-82Q (middle panels) or CBA/Gfa2(B)3-HTT171-82Q viral vectors 
(lower panels). Scale bar = 20µm (n=8-10/group).  
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(B) Quantifications of total number of mHTT aggregates per mm2 after EM48 
immunohistochemical staining in mouse striatum. Analysis was performed on 3 pictures/section, 
3 sections/n, n=8-10/group). Data represent mean ± SEM. *: p < 0.05, Factorial ANOVA followed 
by LSD Fisher post-hoc tests, points represent individual samples. 
(C) Quantifications of the number of mHTT aggregates with diameter <3µm (white bars) or ≥ 5 
3µm (grey bars) per mm2, after EM48 immunohistochemical staining of mouse striatum. Analysis 
was performed on 3 pictures/section, 3 sections/n, n=8-10/group). Data represent mean ± SEM. 
*: p < 0.05, Student’s t tests, points represent individual samples.  
(D) Immunofluorescence staining showing eGFP, HTT aggregates (Sicgen antibody) and either 
GFAP or NeuN immunolabeling in the striatum of CBA-HTT171-82Q (right panels), Gfa2(B)3-10 
HTT171-82Q (middle panels) and CBA/Gfa2(B)3-HTT171-82Q mice (left panels), at 16 wpi. 
Scale bar = 5µm. 
Figure 4: Evolution of the DARPP-32 loss in mice expressing mHTT in neurons, in astrocytes or 
in both neurons and astrocytes 
(A-B) Immunohistochemical staining of DARPP-32 protein in CBA-HTT171 (upper panels), 15 
Gfa2(B)3-HTT171 (middle panels) and CBA/Gfa2(B)3-HTT171 mice (lower panels), expressing 
mutant (A) or control HTT (B, n=8-10/group). 
(C) RT-qPCR on Ppp1r1b mRNA performed on striatum extracts of HTT171-82Q (black bars) or 
HTT171-18Q (gray bars) in each model from 4 to 16 wpi (n=8-10/group). Expression levels are 
normalized with Cyclophilin A (Ppia). Data represent mean ± SEM. *: p < 0.05, Factorial ANOVA 20 
followed by LSD Fisher Post-Hoc tests. AU = Arbitrary Units, RE = Relative Expression. 
Figure 5: Transcriptional and morphologic analyses of striatal astrocytes  
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(A) RT-qPCR on Gfap mRNA performed on mouse striatum between mice expressing HTT171-
82Q (black bars) and HTT171-18Q (gray bars) at 4, 8, 12 or 16 wpi (n=7-10/group). Expression 
levels are normalized with Cyclophilin A (Ppia). Data represent mean ± SEM, Factorial ANOVA 
followed by LSD Fisher Post-Hoc tests. AU = Arbitrary Units, RE = Relative Expression. 
(B) Quantifications of labeling integrated density in Gfap-positive cells after 5 
immunohistochemical staining of mouse striatum at 16 wpi. Analysis was performed on 6 
pictures/section, 3 sections/n, n=8-10/group). Data represent mean ± SEM. *: p < 0.05, 
Student’s t tests. 
(C) Quantifications of the total area occupied by Gfap-positive cells after immunohistochemical 
staining of mouse striatum at 16 wpi (data are expressed in µm2). Analysis was performed on 6 10 
pictures/section, 3 sections/n, n=8-10/group). Data represent mean ± SEM. *: p < 0.05, 
Student’s t tests. 
(D) Representative pictures of immunohistochemical Gfap staining in the striatum of 
CBA/Gfa2(B)3-HTT171-82Q mice (left panel) and CBA/Gfa2(B)3-HTT171-18Q mice (right 
panel). Black arrows show GFAP-positive astrocytes. Scale bar = 20µm.  15 
Figure 6: Analysis of transcriptional dysfunctions in glutamate-glutamine cycle key elements 
caused by neuronal or astrocytic mHTT 
(A-D) Slc1a2 (Glt1, A), Slc1a3 (Glast, B), Atp1a2 (C) and Glul (Gs, D) mRNA levels were 
evaluated in striatum extracts of mice injected with CBA-HTT171 (upper panels), Gfa2(B)3-
HTT171 (middle panels) or CBA/Gfa2(B)3-HTT171 (lower panels) viral vectors. Black bars 20 
represent mice expressing mHTT (HTT171-82Q) and grey bars represent control groups 
(HTT171-18Q). All expression levels are normalized with Cyclophilin A (Ppia). Data represent 
mean ± SEM. *: p < 0.05, #: p=0.051 or 0.052. Factorial ANOVA followed by LSD Fisher Post-
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Hoc tests (n=6-10/group). AU = Arbitrary Units, RE = Relative Expression, GOI = Gene of 
Interest. 
(E) Quantification of Glt1 protein levels after immunoblots on striatal extracts and normalization 
with the total protein content (n=6-9/group). Data represent mean ± SEM. *: p < 0.05, Student’s t 
tests. 5 
(F-G) Grin1 (F) and Grin2b (G) mRNA levels were evaluated in striatum extracts of mice injected 
with CBA-HTT171 (left panels), Gfa2(B)3-HTT171 (middle panels) or CBA/Gfa2(B)3-HTT171 
(right panels) viral vectors. All expression levels are normalized with Cyclophilin A (Ppia). Data 
represent mean ± SEM. *: p < 0.05, NS: p ≥ 0.05, Factorial ANOVA followed by LSD Fisher 
Post-Hoc tests (n=6-10/group). AU = Arbitrary Units, RE = Relative Expression. 10 
Figure 7: Heat maps of correlation analyses between behavioral performances and mRNA levels 
(A-C) Heat maps representing positive (red scale) and negative (blue scale) Pearson 
correlations between behavioral scores and mRNA expression levels of DARPP-32 (red), 
Glutamate/Glutamine cycle (Glut./glu, green), NMDAR (clear gray) or astrogliosis (GFAP, dark 
gray) in CBA-HTT171 (A), Gfa2(B)3-HTT171 (B), or CBA/Gfa2(B)3-HTT171 mice (C). Analysis 15 
was performed in each model separately, both on HTT171-82Q and HTT171-18Q mice at all 
time points. Numbers represent R score. Yellow numbers represent FDR < 0.05, Pearson 
correlations followed by p. value corrected for False Discovery Rate (n=37-40/group). 
Figure 8: Graphical representation of the progression of each HD mouse model 
(A-C) Schematic representation of neuronal (A), astrocytic (B) or double (C) mouse models, at 4, 20 
8, 12 and 16 wpi (x-axis). Blue lines represent behavioral dysfunctions, red lines represent 
typical HD pathological hallmarks, and green lines represent transcriptional dysfunctions of 
Glutamate/Glutamine cycle elements. The absence or the intensity of dysfunctions is 
represented in the y-axis. 
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Figure 1: Characterization of human HTT expression induced by cell-type specific AAV2/5  
(A) Representative confocal pictures of mouse striatum 3 weeks post injection of CBA-eGFP (upper panels) 
or Gfa2(B)3-eGFP AAV2/5 (lower panels). In CBA-eGFP mice, co-immunolabeling with a neuronal marker 
(NeuN, Neuronal nuclei) was performed, whereas in Gfa2(B)3-eGFP a co-immunolabeling with Glutamine 
Synthetase (GS), a marker of astrocytes, was performed. Scale bar = 20µm.  
(B) Quantifications of the percentage of eGFP-positives cells that co-localized with NeuN or with GS, three 
weeks after injection of CBA-eGFP or Gfa2(B)3-eGFP AAV2/5 in mouse striatum. Data are presented as 
mean ± SEM, quantifications were performed on 4-6 pictures/section, 4 sections/n, n= 4.  
(C) AAV2/5 vectors allowed expression of either control HTT171-18Q-HA (blue cells) or mutant HTT171-82Q 
(red cells), in neurons (CBA), in astrocytes (Gfa2(B)3), or in both neurons and astrocytes (CBA/Gfa2(B)3), 
depending on the promoter. Forty mice/group were used in each experimental condition.. WPRE = 
Woodchuck Post-Regulatory Element, bGH = sequence of the polyadenylation signal of Bovine Growth 
Hormone gene. Gray boxes correspond to Inverted Terminal Repeats regions of AAV2.  
(D) RT-qPCR on total HTT (totHTT) was performed on striatum extracts from CBA-HTT171-82Q, Gfa2(B)3-
HTT171-82Q and CBA/Gfa2(B)3-HTT171-82Q mice at 4, 8, 12 or 16 wpi, compared to non-injected mice 
(n=8-10/group, except for non-injected mice: n=5). Expression levels are normalized with Cyclophilin A 
levels (Ppia). Data represent mean ± SEM. *: p < 0.05, NS (Not Significant): p ≥ 0.05, Factorial ANOVA 
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Figure 2: Behavioral alterations after mHTT expression in neurons, in astrocytes or in both cell-types.  
(A) Ratio of distance traveled in the external field/the total distance traveled by the HTT171-18Q mice (gray 
bars) or HTT171-82Q mice (black bars) during the Open Field task (n=9-10/group). Data represent mean ± 
SEM. *: p < 0.05, Factorial ANOVA followed by LSD Fisher Post-Hoc tests, points represent individual 
samples.  
(B) Total distance travelled was measured as an index of mouse spontaneous motor activity in the Open 
Field task (in meters, m, n=9-10/group). Data represent mean ± SEM. *: p < 0.05, Factorial ANOVA 
followed by LSD Fisher Post-Hoc tests, points represent individual samples.  
(C) Graphic representing latency to fall (in second, sec.) of mice during Rotarod Accelerated Test n=9-
10/group). Data represent mean ± SEM of the three trials of each days. *: p < 0.05, Repeated-Measures 
ANOVA followed by LSD Fisher Post-Hoc tests.  
(D) Evaluation of clasping movements represented by the number of paw clasping (n=9-10/groups). Data 
represent mean ± SEM. *: p < 0.05, Factorial ANOVA followed by LSD Fisher Post-Hoc tests, points 
represent individual samples.  
(E) Mouse body weight gain was evaluated between the surgery and euthanasia at 4, 8, 12 or 16 wpi. Data 
are presented in grams (g), and represent mean ± SEM. *: p < 0.05, Factorial ANOVA followed by LSD 
Fisher Post-Hoc tests, points represent individual samples.  
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Figure 3: mHTT aggregation patterns between striatal neurons and astrocytes  
(A) Representative pictures of immunohistochemical staining of mHTT aggregates with EM48 antibody at 4, 
8, 12 and 16 wpi, in the striatum of mice injected with CBA-HTT171-82Q (upper panels), Gfa2(B)3-HTT171-
82Q (middle panels) or CBA/Gfa2(B)3-HTT171-82Q viral vectors (lower panels). Scale bar = 20µm (n=8-
10/group).  
(B) Quantifications of total number of mHTT aggregates per mm2 after EM48 immunohistochemical staining 
in mouse striatum. Analysis was performed on 3 pictures/section, 3 sections/n, n=8-10/group). Data 
represent mean ± SEM. *: p < 0.05, Factorial ANOVA followed by LSD Fisher post-hoc tests, points 
represent individual samples.  
(C) Quantifications of the number of mHTT aggregates with diameter <3µm (white bars) or ≥ 3µm (grey 
bars) per mm2, after EM48 immunohistochemical staining of mouse striatum. Analysis was performed on 3 
pictures/section, 3 sections/n, n=8-10/group). Data represent mean ± SEM. *: p < 0.05, Student’s t tests, 
points represent individual samples.  
(D) Immunofluorescence staining showing eGFP, HTT aggregates (Sicgen antibody) and either GFAP or 
NeuN immunolabeling in the striatum of CBA-HTT171-82Q (right panels), Gfa2(B)3-HTT171-82Q (middle 
panels) and CBA/Gfa2(B)3-HTT171-82Q mice (left panels), at 16 wpi. Scale bar = 5µm.  
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Figure 4: Evolution of the DARPP-32 loss in mice expressing mHTT in neurons, in astrocytes or in both 
neurons and astrocytes  
(A-B) Immunohistochemical staining of DARPP-32 protein in CBA-HTT171 (upper panels), Gfa2(B)3-HTT171 
(middle panels) and CBA/Gfa2(B)3-HTT171 mice (lower panels), expressing mutant (A) or control HTT (B, 
n=8-10/group).  
(C) RT-qPCR on Ppp1r1b mRNA performed on striatum extracts of HTT171-82Q (black bars) or HTT171-18Q 
(gray bars) in each model from 4 to 16 wpi (n=8-10/group). Expression levels are normalized with 
Cyclophilin A (Ppia). Data represent mean ± SEM. *: p < 0.05, Factorial ANOVA followed by LSD Fisher 
Post-Hoc tests. AU = Arbitrary Units, RE = Relative Expression.  
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Figure 5: Transcriptional and morphologic analyses of striatal astrocytes  
(A) RT-qPCR on Gfap mRNA performed on mouse striatum between mice expressing HTT171-82Q (black 
bars) and HTT171-18Q (gray bars) at 4, 8, 12 or 16 wpi (n=7-10/group). Expression levels are normalized 
with Cyclophilin A (Ppia). Data represent mean ± SEM, Factorial ANOVA followed by LSD Fisher Post-Hoc 
tests. AU = Arbitrary Units, RE = Relative Expression.  
(B) Quantifications of labeling integrated density in Gfap-positive cells after immunohistochemical staining of 
mouse striatum at 16 wpi. Analysis was performed on 6 pictures/section, 3 sections/n, n=8-10/group). Data 
represent mean ± SEM. *: p < 0.05, Student’s t tests.  
(C) Quantifications of the total area occupied by Gfap-positive cells after immunohistochemical staining of 
mouse striatum at 16 wpi (data are expressed in µm2). Analysis was performed on 6 pictures/section, 3 
sections/n, n=8-10/group). Data represent mean ± SEM. *: p < 0.05, Student’s t tests.  
(D) Representative pictures of immunohistochemical Gfap staining in the striatum of CBA/Gfa2(B)3-HTT171-
82Q mice (left panel) and CBA/Gfa2(B)3-HTT171-18Q mice (right panel). Black arrows show GFAP-positive 
astrocytes. Scale bar = 20µm.  
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Figure 6: Analysis of transcriptional dysfunctions in glutamate-glutamine cycle key elements caused by 
neuronal or astrocytic mHTT  
(A-D) Slc1a2 (Glt1, A), Slc1a3 (Glast, B), Atp1a2 (C) and Glul (Gs, D) mRNA levels were evaluated in 
striatum extracts of mice injected with CBA-HTT171 (upper panels), Gfa2(B)3-HTT171 (middle panels) or 
CBA/Gfa2(B)3-HTT171 (lower panels) viral vectors. Black bars represent mice expressing mHTT (HTT171-
82Q) and grey bars represent control groups (HTT171-18Q). All expression levels are normalized with 
Cyclophilin A (Ppia). Data represent mean ± SEM. *: p < 0.05, #: p=0.051 or 0.052. Factorial ANOVA 
followed by LSD Fisher Post-Hoc tests (n=6-10/group). AU = Arbitrary Units, RE = Relative Expression, GOI 
= Gene of Interest.  
(E) Quantification of Glt1 protein levels after immunoblots on striatal extracts and normalization with the 
total protein content (n=6-9/group). Data represent mean ± SEM. *: p < 0.05, Student’s t tests.  
(F-G) Grin1 (F) and Grin2b (G) mRNA levels were evaluated in striatum extracts of mice injected with CBA-
HTT171 (left panels), Gfa2(B)3-HTT171 (middle panels) or CBA/Gfa2(B)3-HTT171 (right panels) viral 
vectors. All expression levels are normalized with Cyclophilin A (Ppia). Data represent mean ± SEM. *: p < 
0.05, NS: p ≥ 0.05, Factorial ANOVA followed by LSD Fisher Post-Hoc tests (n=6-10/group). AU = Arbitrary 
Units, RE = Relative Expression.  
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Figure 7: Heat maps of correlation analyses between behavioral performances and mRNA levels  
(A-C) Heat maps representing positive (red scale) and negative (blue scale) Pearson correlations between 
behavioral scores and mRNA expression levels of DARPP-32 (red), Glutamate/Glutamine cycle (Glut./glu, 
green), NMDAR (clear gray) or astrogliosis (GFAP, dark gray) in CBA-HTT171 (A), Gfa2(B)3-HTT171 (B), or 
CBA/Gfa2(B)3-HTT171 mice (C). Analysis was performed in each model separately, both on HTT171-82Q 
and HTT171-18Q mice at all time points. Numbers represent R score. Yellow numbers represent FDR < 0.05, 
Pearson correlations followed by p. value corrected for False Discovery Rate (n=37-40/group).  
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Figure 8: Graphical representation of the progression of each HD mouse model  
(A-C) Schematic representation of neuronal (A), astrocytic (B) or double (C) mouse models, at 4, 8, 12 and 
16 wpi (x-axis). Blue lines represent behavioral dysfunctions, red lines represent typical HD pathological 
hallmarks, and green lines represent transcriptional dysfunctions of Glutamate/Glutamine cycle elements. 
The absence or the intensity of dysfunctions is represented in the y-axis.  
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Supplemental Experimental Procedures – See also Experimental Procedures 
Animals 
Males C57Bl/6RJ mice were provided by Janvier Labs (Le Genest-Saint-Isle, France) at 10 weeks old. Mice were 
housed in large plastic cages containing one grid, one house, two tunnels and tree towels (cage size = 916 cm
2
, 
5mice/cage), in temperature controlled environment (22±1°C) on a 12hr light/dark cycle. All mice were individually 
handled twice per weeks, and cages were changed once per week by the same experimentator. In case of 
aggressiveness in 82Q groups, mice were isolated in separate cage. To avoid potential isolation effect on behavioral 
tests, the same number of mice from 18Q group was isolated. Food and water were provided ad libitum.  
Plasmids cloning and AAVs production 
Plasmids:  
Plasmid containing Gfa2(B)3 promoter was kindly provided by Dr. Michael Brenner through the support of NIH 
grant NS39055. Cassette encoding Gfa2(B)3 (2.2kb, (de Leeuw et al., 2006) was removed from pUC-Gfa2(B)3-nls-
LacZ and subsequently cloned into pAAV2aa-ITR-GfaABC1D-RFA-WPRE-bGH-ITR to obtain pAAV2ss-ITR-
Gfa2(B)3-RFA-WPRE-bGH-ITR plasmid. Plasmids pENTR4-HTT171-18Q-HA and pENTR4-HTT171-82Q were 
already available in the laboratory (De Almeida et al., 2002). Gateway LR Clonase® reaction (Invitrogen, 
ThermoFisher Scientific, ref. 11791-019) was performed to insert HTT171-82Q, HTT171-18Q-HA , mCherry or 
eGFP (Clonetech, Saint-Germain-en-Laye, France) cassettes from pENTR4 plasmids into destination vectors. Final 
products generated were as follow: pAAV2ss-ITR-Gfa2(B)3-eGFP-WPRE-bGH-ITR, pAAV2ss-ITR-Gfa2(B)3-
HTT171-82Q-HA-WPRE-bGH-ITR, pAAV2ss-ITR-Gfa2(B)3-HTT171-18Q-HA-WPRE-bGH-ITR, pAAV2ss-ITR-
CBA-eGFP-WPRE-bGH-ITR, pAAV2ss-ITR-CBA-HTT171-82Q-HA-WPRE-bGH-ITR, pAAV2ss-ITR-CBA-
HTT171-18Q-HA-WPRE-bGH-ITR and pAAV2ss-ITR-CBA-mCherry-WPRE-bGH-ITR respectively.  
AAVs production: 
AAVs were produced in HEK293T cells (mycoplasma negative, ATCC, LGC Standards GmbH). pDG5rs-Cap-Rep 
(Rep-Cap-Helper; Plasmid Factory, Bielefeld, Germany) and pAAV2ss containing the transgene of interest were 
transfected by calcium phosphate precipitation. Cells and supernatant were harvested 72h post-transfection and 
centrifuged at 300g for 10 minutes at 4°C. Supernatant was supplemented with 8% PEG (Sigma-Aldrich, Buchs, 
Switzerland) 2.5M NaCl (Merck, Nottingham, UK) and was kept at 4°C for at least 2 hours. Cell pellets were pooled 
and incubated in lysis buffer (NaCl 0.15M, Merck, Nottingham, UK, Tris-HCl 50mM, pH 8.5, Sigma-Aldrich, 
Buchs, Switzerland) for 3 consecutive freeze/thaw cycles (30 minutes in dry ice/ethanol followed by 30 minutes at 
37°C). PEG-containing supernatant was centrifuged at 4’000 g for 20 minutes at 4°C after the 2 hours incubation and 
supernatant was discarded. Cell lysate was added to the pellets and the mixture was incubated at 37°C for 1 hour to 
ensure full homogenization of pellets. Lysate was then treated with benzonase (0.15 units, Sigma-Aldrich, Buchs, 
Switzerland) in filtered MgCl2 1M at 37°C for 30 minutes (Sigma-Aldrich, Buchs, Switzerland). Treated lysate was 
clarified by centrifugation at 4’000 g for 20 minutes at 4°C. AAV were separated using iodixanol (AxonLab, Le 
Mont sur Lausanne, Switzerland) gradient ultracentrifugation at 59’000 rpm (70Ti rotor, Beckman-Coulter, Nyon, 
Switzerland) for 90 minutes at 20°. Phase containing AAV was harvested and loaded on an Amicon Ultra-15 PL 100 
column (Millipore, Zug, Switzerland) with 0.001% Pluronic F68 D-PBS (Gibco, ThermoFisher Scientific, Waltham, 
USA, Zug, Switzerland) for iodixanol cleaning and viral particles concentration. Tubes were first centrifuged at 
4’000 g at 4°C until the whole solution has passed through the column. Two additional wash with 0.001% Pluronic 
F68 D-PBS were done and AAV were finally suspended in 250-500µL 0.001% Pluronic F68 D-PBS. The viral 
genomes content (vg/ml) of each AAV2/5 was assessed by Taqman® qPCR with primers recognizing Inverted 
Terminal Repeats of AAV2 viral genome (primer forward: 5’- GGAACCCCTAGTGATGGAGTT-3’, primer 
reverse: 5’-CGGCCTCAGTGAGCGA-3’, Taqman® probe: 5’-CACTCCCTCTCTGCGCGCTCG-3’). The titers of 
the different batches were as follow: AAV2/5-CBA-eGFP: 1.8E10
11
vg/ml; AAV2/5-CBA-mCherry: 3.7E10
11
vg/ml; 
AAV2/5-CBA-HTT171-18Q: 8.3E10
10
vg/ml; AAV2/5-CBA-HTT171-82Q: 3.5E10
11
vg/ml; AAV2/5-Gfa2(B)3-
eGFP: 1.4E10
10
vg/ml; AAV2/5-Gfa2(B)3-HTT171-18Q: 8.5E10
11
vg/ml; AAV2/5-Gfa2(B)3-HTT171-82Q: 
2.1E10
12
vg/ml. AAV2/5 vectors were stored at -80°C until use. 
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Injections 
Stereotaxic surgeries: 
Surgeries were performed at 11 weeks old. Mice were randomly assigned to experimental groups. Mice were 
anesthetized with intra-peritoneal injection of a mix of Ketamine (100mg/kg, Ketasol ®, Graeub, Bern, Switzerland) 
and Xylazine (10mg/kg, Rompun ®, Bayer Health Care, Uznach, Switzerland) in Sodium Chloride 0.9% (NaCl, B-
BRAUN, Melsungen, Germany). The head of the mouse was shaved, and the animal was placed on the stereotaxic 
frame (Model 963 Ultra Precise Small Animal Stereotaxic Instrument, Kopf, Tujunga, USA). The mouse 
temperature was monitored and kept constant (>36°C), and Viscotears ® (Swissmedic, Bern, Switzerland) was 
continuously applied on eyes to avoid drying. Liquid Betadine ® was applied to clean the skin before incision and 
exposure of the skull. A 25G needle fixed to a syringe holder was used to pierce the skull at appropriate coordinates. 
All injections were performed bilaterally. For tropism validation, CBA-eGFP and Gfa2(B)3-eGFP viral vectors were 
injected in one site/hemisphere (AP: +1 ; ML: ±1.5 ; DV: -3.5). For diffusion analysis, CBA-mCherry and Gfa2(B)3-
eGFP vectors were co-injected in two sites/hemisphere (anterior striatum = AP: +1 ; ML: ±1.5 ; DV: -3.5 ; posterior 
striatum = AP: 0 ; ML: ±2 ; DV: -3.5). For neuron or astrocyte specific HD mouse models, CBA-HTT171-82Q, 
CBA-HTT171-18Q, Gfa2(B)3-HTT171-82Q or Gfa2(B)3-HTT171-18Q viral vectors were injected with either 
CBA-eGFP or Gfa2(B)3-eGFP vectors in two sites/hemisphere. For CBA/Gfa2(B)3-HTT171 mice, CBA-HTT171-
82Q and Gfa2(B)3-HTT171-82Q, or CBA-HTT171-18Q and Gfa2(B)3-HTT171-18Q vectors were co-injected, 
together with CBA-eGFP viral vectors. Viral vectors were injected with 34G steel cannulas (Unimed, Lausanne, 
Switzerland) fixed on a cannula holder and linked to an 10µl Hamilton syringe and an infusion pump (CMA 4004, 
Phymep, Paris, France). For each site, 2µl of viral vector was injected at 0.2µl/min. Cannulas were left in the brain 
for 5 minutes after injection, and then slowly removed. Skin was closed using 6.0 sterile suture thread (Novosyn 
DS12, B-BRAUN, Melsungen, Germany). Sterile NaCl 0.9% solution was delivered to the mouse by sub-cutaneous 
injection to avoid dehydration after surgery, and healing cream (Bepanthen®Plus, BAYER, Leverkusen, Germany) 
was applied on the head. Sugar-taste Paracetamol (Dafalgan ®, UPSA, Agen, France) was delivered to the mice in 
water (500mg/cage) during 72h. Mice were monitored until complete awakening, and every day during three days 
after surgery. 
Viral vectors doses:  
All viral vectors were injected in a final volume of 2µl/sites. For tropism study, CBA-eGFP was injected at 5E10
7
 
viral genomes (vg)/sites. Due to low viral titer, Gfa2(B)3-eGFP vector was injected at 2.75E10
7
 vg/site. To evaluate 
the diffusion of AAV2/5 in basal ganglia circuit, we co-injected CBA-mCherry and Gfa2(B)3-eGFP at 5E10
7
 
vg/sites per viral vector. AAV2/5 containing CBA-HTT171 were co-injected with AAV2/5 containing CBA-eGFP at 
5E10
7
 vg/site and 4E10
6
 vg/sites respectively. AAV2/5 containing Gfa2(B)3-HTT171 were co-injected with AAV2/5 
containing Gfa2(B)3-eGFP at 5E10
7
 vg/site and 4E10
6
 vg/sites respectively. The co-injection of CBA-HTT171-82Q 
and Gfa2(B)3-HTT171-82Q, or CBA-HTT171-18Q and Gfa2(B)3-HTT171-18Q were performed with 5E10
7
 
vg/sites/viral vector, in combination with 4E10
6
 vg/site of CBA-eGFP vector.  
Behavioral tests 
Each mouse was habituated to the room and to the experimentator by individual handling during 1min./day during 
three days before behavioral tests. The total duration of tests was one week, in the following order: Open Field, 
Rotarod Accelerated test, Clasping test, weight follow-up, EchoMRI. 
Open Field 
Mouse was placed in the center of a circular gray arena (diameter = 75 cm, home-made) and was free to explore 
during 30 min. Automated recording of mouse movements were performed using video camera coupled to tracking 
analysis by Anymaze © software (software available on: http://www.anymaze.com/). Extern field correspond to a 10 
cm band along the walls, and Intern field was all the remaining area. We analyzed the total distance traveled by the 
mouse, and the distance traveled in extern field of the arena.  
Rotarod Accelerated Test 
Rotarod Accelerated test was performed on UGO-BASILE apparatus (model 7600, Ugo-Basile, Comerio-Varese, 
Italy), consisting of five equal compartments on a plastic-gripped cylinder. Groups of mice evaluated at the same 
time were kept constant to avoid increased anxiety. Mice were first trained during 5min. at 4 rotations per minutes 
Page 43 of 52
John Wiley & Sons, Inc.
GLIA
(rpm) for habituation. Tests were conducted during three trials per days (with 45 min. resting between each trial) 
during three consecutive days. For each trial, mice were placed on the rod that accelerate from 4 to 40 rpm in 5 min. 
Latency to fall (or if mice hung on for more than two consecutive rotations without running) was recorded.  
Clasping Test 
Mice were individually suspended by the experimentator at the last third of the tail during 30 sec., at 1.5 m. from the 
floor. Two blind observers rated the number of paw clasping, corresponding to the clasping score (1 = one anterior 
paw, 2 = two anterior paws, 3 = two anterior paws and one posterior paw, 4 = four paws, adapted from Fink et al., 
2013).  
Weight follow-up and EchoMRI 
Mice were weighted the day of the surgery and the day before euthanasia at 4, 8, 12 or 16 wpi. The weight difference 
between the two time-points was considered as the weight gain. Whole body composition analysis was performed 
with EchoMRI ® Analyzer (Houston, USA). We measured the whole body masses of fat and lean.  
Cell cultures and transfections 
HEK293T cells were cultured in DMEM medium (Gibco, ThermoFisher Scientific, Waltham, USA, ref. 32430027), 
completed with 10% Fetal Bovine Serum (Gibco, ThermoFisher Scientific, Waltham, USA, ref. 10270-106) and 1% 
of Peniciline-Streptomycin (Gibco, ThermoFisher Scientific, Waltham, USA, ref. 15140-122). pAAV2ss CBA-
HTT171-82Q and CBA-HTT171-18Q-HA plasmids were transfected by calcium-phosphate precipitation. HEPES 
buffer (Sigma-Aldrich, Buchs, Switzerland, ref. n°51558) and 0.5M CaCl2 solution (Merck, Darmstadt, Germany, 
ref. TA799582) were mixed together with 4µg of plasmid (300.000 cells per well in a 6-well plate, Vitaris, Baar, 
Switzerland). Medium were changed 6h after transfection. Three days after transfection, cells were washed two times 
with HBSS (Gibco, ThermoFisher Scientific, Waltham, USA, ref. 14025092) and lysed in 1mL of TRIzol Reagent ® 
(Ambion, ThermoFisher Scientific, Waltham, USA, ref. 15596-026).  
Brain samples processing 
All procedure for brain dissection was performed under RNAse-free conditions. Mice were anesthetized by lethal i.p 
injection of Pentobarbital (150mg/kg, Esconarkon, Streuli Pharma, Uznach, Switzerland). After decapitation, brain 
was quickly removed and placed in a cold dissection matrix to isolate 1mm slices. Brain slices were placed under 
inverted Fluorescent Microscope (Olympus IX 81) to quickly dissect eGFP-positive area in the striatum. Punches 
were immediately homogenized on ice in 200µl of TRIzol Reagent® solution (Invitrogen, ThermoFisher Scientific, 
Waltham, USA, ref. 15596026), completed until 1ml, and stocked at -80°C.  
For brain fixation, mice were anesthetized by lethal i.p injection of Pentobarbital (150mg/kg, Esconarkon, Streuli 
Pharma, Uznach, Switzerland). Intra-cardiac perfusion of cold Phosphate-buffered saline (PBS 1X) was performed 
during 1min. (20ml/min.), followed by perfusion of cold fresh Paraformaldehyde (4%) solution diluted in 0.15M Na-
Phosphate buffer during 5 min (20ml/min.). Brain was next quickly dissected and post-fixed in Paraformaldehyde 
solution during additional 12h, followed by cryo-protection in PBS 1X-Sucrose 20% (12h) and PBS 1X-Sucrose 
30% (12h). Brains were conserved at -80°C until use.  
RNA and protein extraction:  
RNA and protein extractions were performed according to TRIzol Reagent ® kit recommendations (Invitrogen, 
ThermoFisher Scientific, Waltham, USA, ref. 15596026). All extractions were performed on ice under RNAse free 
conditions, with ultrapure sterile RNAse-DNAse free water (Invitrogen, ThermoFisher Scientific, Waltham, USA, 
ref. 10977-049). HTT171-18Q and HTT171-82Q samples were extracted at the same time. Glycogen (10µg, 
Invitrogen, ThermoFisher Scientific, Waltham, USA, ref. 10814-010) was added before RNA extraction to improve 
RNA pellet visualization. RNA washes with 75% ETOH were performed twice, and pellet was finally suspended in 
22µl (in vivo samples) or 52µl (in vitro samples) of ultrapure water and stored at -80°C. RNA concentration and 
potential chemical contaminations were evaluated by Nanodrop® (ND-1000 Spectrophotometer, Witec, Luzern, 
Switzerland). Samples with aberrant A260/280 or A260/230 ratios were discarded.  
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Protein extractions were performed according to TRIzol ® kit recommendations (Invitrogen, ThermoFisher 
Scientific, Waltham, USA, ref. 15596026). Samples were resuspended at the end of the extraction in a solution 
containing 2/3 SDS 1% (Invitrogen, ThermoFisher Scientific, Waltham, USA, ref. 15525-017) and 1/3 Urea 10M 
(Acros Organics, Geel, Belgium, ref. 327380010), at 95°C during 30min on agitation (300rpm), then stored at -20°C. 
Protein concentration was evaluated using Micro BCA
TM
 Protein assay kit (ThermoFicher Scientific, Waltham, USA, 
ref. 23235), according to kit recommendations.  
Immunohistochemistry and image acquisitions 
Primary and secondary antibodies are detailed in following tables. For fluorescent labeling, 20µm free-floating 
sections were washed three times (10min./wash) at room temperature (RT) in PBS 1X, blocked 1h in PBS 1X 
containing 5% Donkey Serum (Sigma-Aldrich, Buchs, Switzerland, ref. D9663) and 0.1% Triton (Sigma-Aldrich, 
Buchs, Switzerland, ref. X-100). Sections were incubated overnight at 4°C in PBS 1X containing 0.1% Triton, 5% 
Donkey Serum and primary antibodies. The following day sections were washed three times in PBS 1X and 
incubated 2h in PBS 1X containing 5% Donkey Serum, 0.1% Triton and secondary antibodies. Sections were finally 
washed three-times in PBS 1X, incubated in Hoechst33342 trihydrochloride trihydrate solution (10µg/ml, Invitrogen, 
ThermoFicher Scientific, Waltham, USA, ref. H3570) during 5min at RT., rinsed three times in PBS 1X and mount 
on SuperFrost Ultra Plus microscope slides (ThermoFicher Scientific, Waltham, USA, ref. J3800AMNZ) in 
Fluoromount medium (Sigma-Aldrich, Buchs, Switzerland, ref. F4680).  
For chromogen-based labeling, 20µm sections were treated with tris-buffered saline (TBS, Tris 10mM, AppliChem, 
Darmstadt, Germany, ref.A1087, 0.9% NaCl, Sigma-Aldrich, Buchs, Switzerland, ref. A2942) containing 3% 
hydrogen peroxide (Sigma-Aldrich, Buchs, Switzerland, ref. 31642) and 10% Methanol (ThermoFicher Scientific, 
Waltham, USA, ref. M/4058/17) during 15 min. to quench endogenous peroxidase activity. Sections were rinsed 
three-times in TBS, incubated 1h at RT in TBS containing 0.1% Triton and 5% of Bovine Serum Albumine Fraction 
V (BSA, AppliChem, Darmstadt, Germany, ref. A1391) followed by overnight incubation at 4°C in TBS containing 
0.1% Triton, 1% BSA and primary antibody. The following day, sections were washed three times in TBS, incubated 
in TBS containing 0.1% Triton, 1% BSA and appropriate biotinylated secondary antibody during 2h at RT, and 
developed with avidin-biotinylated horseradish peroxidase complexes for 1h at RT (Vector Labs, Burlingame, 
Canada, ref. PK6200). Immunoreactivity was revealed using either nickel-amonium sulfate and diaminobenzidine 
(DAB, black reaction) or only DAB following kit recommendations (Vectors Labs, Burlingame, Canada, ref. SK-
4100). HTT171-18Q and HTT171-82Q samples were processed in parallel with identical revelation conditions 
between all groups. Sections were dehydrated in ethanol followed by xylene (Sigma-Aldrich, Buchs, Switzerland, 
ref. X1040), and mount on Superfrost Ultra Plus microscope slides with Eukitt® medium (Sigma-Aldrich, Buchs, 
Switzerland, ref. 03989).  
Fluorescent images were captured using inverted Zeiss LSM 510 Meta confocal microscope (Supplemental Figure 
1B) or inverted Zeiss LSM 880 confocal microscope (all other fluorescent pictures). Images of DAB 
immunohistochemistry were captured using upright Zeiss Axio Imager.Z1. For quantitative analysis, all acquisition 
parameters were kept constant between samples and between groups. Quantifications of EM48-positives mHTT 
aggregates and Gfap-positive cells were performed manually with ImageJ 1.44p software and the Cell Counter 
plugin. Analysis of Integrated Density and area of Gfap immunolabeling were automatically performed with home-
made macro in ImageJ 1.44p (software available on: http://imagej.nih.gov/ij/index.html). All analyses were 
performed on raw unmodified images. To aid visualization, some panels of DAB immunohistochemistry comprises 
images with subsequent adjustments of brightness and contrast made in Photoshop (CS6, Adobe, software available 
on: http://www.adobe.com/ch_fr/products/photoshop.html), adjustments were identical between groups.  
List of primary antibodies:  
Primary antibody Host organism Dilution Product Reference 
(RRID) 
GFP Goat 1:1000 Sicgen, AB0020-200 
(RRID: AB_2333099) 
mCherry Goat 1:1000 Sicgen, AB0040-200 
(RRID: AB_2333092) 
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HTT (EM48) Mouse 1:100 Millipore, MAB5374 
(RRID: AB_10055116) 
HTT (Sicgen) Goat 1:1000 Sicgen, AB0080-200 
(RRID: AB_2333150) 
NeuN (Figure 1, tropism 
quantifications) 
Mouse 1:500 Millipore, MAB377 
(RRID: AB_10048713) 
NeuN (Figure 4, 
Supplemental Figure S3 
and S5) 
Rabbit 1:1000 Millipore, ABN78 (RRID: 
AB_11211087) 
GFAP Rabbit 1:500 DakoCytomation, Z0334 
(RRID: 2314535) 
GS Rabbit 1:1000 Sigma-Aldrich, G2781 
(RRID: AB_259853) 
DARPP-32 Rabbit 1:1000 Cell Signaling, 2302S 
(RRID: AB_10691682) 
 
List of secondary antibodies: 
Secondary antibody Host organism Dilution Product reference 
(RRID) 
Alexa Fluor 488 
conjugated anti-goat 
Donkey 1:500 Thermo Fisher Scientific, 
A11055 (RRID: 
AB_10564074) 
Cy3 conjugated anti-goat Donkey 1:500 Jackson Immunoresearch, 
705-166-147 (RRID: 
AB_2340413) 
Cy3 conjugated anti-
mouse 
Donkey 1:500 Jackson Immunoresearch 
715-166-150 (RRID: 
AB_2340816) 
Alexa Fluor 594 
conjugated anti-rabbit 
Donkey 1:500 Jackson Immunoresearch 
711-586-152 (RRID: 
AB_2340622) 
Cy5 conjugated anti-rabbit Donkey 1:500 Jackson Immunoresearch 
711-175-152 (RRID: 
AB_2340607) 
Biotinylated anti-mouse Horse 1:400 Vector Laboratories, 
BA2000 
(RRID:AB_2313581) 
Biotinylated anti-rabbit Goat 1:500 Vector Laboratories, 
BA1000 (RRID: 
AB_2313606) 
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 RT-qPCR 
Primer sequences are detailed in the following table. mRNAs were treated with DNAse enzyme (220ng 
mRNA/reaction, RQ1 DNAse 1, Promega, Madison, USA, ref. M6101), according to kit recommendations. cDNA 
synthesis by reverse transcription was performed using Superscript II Reverse Transcriptase enzyme (100ng of 
DNAse-treated mRNA/reaction, ThermoFisher Scientific, Waltham, USA, ref. 18064-014), according to kit 
recommendation (0.5µM Random Hexamers, Invitrogen, ThermoFisher Scientific, Waltham, USA, ref. N8080127, 
and 0.1mM dNTPs, Invitrogen, ThermoFisher Scientific, Waltham, USA, ref. 18427-013). qPCR were performed 
using KAPA SYBR Fast kit (KAPA, Labgene Scientific, Châtel-St-Denis, Switzerland, ref.KK4602). Final mix 
contained 200nM of each primer, 1ng cDNA, 1X ROX High and 1X KAPA SYBR Fast (20µl of total reaction). 
Samples from HTT171-18Q and HTT171-82Q, or from 4, 8, 12 or 16 wpi were homogeneously divided in 96-wells 
qPCR plates (Applied Biosystems, ThermoFisher Scientific, Waltham, USA, ref. 4346907), to allow further 
statistical comparisons. Housekeeping gene (Ppia) was repeated in all reaction plate, to control for inter-plates 
repeatability. Samples were loaded in triplicate and technical replicates with variability ≥ 2% were discarded. 
Negative controls containing KAPA SYBR, primers, ROX High and water were loaded in each plate for each primer 
pair and melting curve analysis was performed to control for contaminations. Normalization on Ppia for each gene 
was performed for each sample, according to following formula (RE = Relative Expression, Cq = quantification 
cycle, GOI = Gene Of Interest):  
 
Targeted gene: Specie: Primers sequences: 
HTT Human and mouse 5’-CCGCTGCACCGACCAAAGAA-3’ 
3’- ATTTCTGAGAGACTGTGCCA-5’ 
HTT Human 5’-CTGCACCGACCAAAGAAAGAAC-3’ 
3’-CATAGCGATGCCCAGAAGTTTC-5’ 
ACTB Human 5’-TGAAGGTGACAGCAGTCGGTTG-3’ 
3’-GGCTTTTAGGATGGCAAGGGAC-5’ 
Ppia Mouse 5’-ATGGCAAATGCTGGACCAAA-3’ 
3’-GCCTTCTTTCACCTTCCCAAA-5’ 
Ppp1r1b Mouse 5’-CCCTGAGCCTGGCACATAAG-3’ 
3’-AAGCCGCAGCCCTAGCA-5’ 
Slc1a2 Mouse 5’-GGCAATCCCAAACTCAAGAAGC-3’ 
3’-GTCACTGTCTGAATCTGCTGGAAAC-5’ 
Slc1a3 Mouse 5’-TCTCCAGTCTCGTCACAGGAATG-3’ 
3’-TGCCAATCACCACAGCAATG-5’ 
Atp1a2 Mouse 5’-GAGACGCGCAATATCTGTTTCTT-3’ 
3’-ACCTGTGGCAATCACAATGC-5’ 
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Glul Mouse 5’-CACCGCTCTGAACACCTTCC-3’ 
3’-TGGCTTGGACTTTCTCACCC-5’ 
Grin1 Mouse 5’-TCCCAACGACCACTTCACTC-3’ 
3’-AGTAGATGGACATTCGGGTAGTC-5’ 
Grin2b Mouse 5’-GCTACAACACCCACGAGAAGAG-3’ 
3’-GAGAGGGTCCACGCTTTCC-5’ 
Gfap Mouse 5’-ACGACTATCGCCGCCAACT-3’ 
3’-GCCGCTCTAGGGACTCGTTC-5’ 
 
Western blot 
Mix containing proteins (20µg for GLT-1 blots or 30µg for HTT blots) and Laemmli buffer 1X (BIO-RAD, Cressier, 
Switzerland, ref. 161-0747) was heated at 95°C during 5min. for denaturation. Samples were run on SDS-PAGE on 
10% acrylamide gels and transferred to 0.2µm nitrocellulose membranes (BIO-RAD, Cressier, Switzerland, ref. 
1704158) with the semi-dry TransBlot-Turbo
TM
 transfer system (BIO-RAD, Cressier, Switzerland). Non-specific 
binding sites were blocked for 1h at RT in tris-buffered saline (TBS, Tris-Hcl pH 7.5 50mM, NaCl 150mM) 
containing 0.1% Tween® (AppliChem, Darmstadt, Germany, ref. A1389) and 5% of nonfat dried milk (Applichem, 
Darmstadt, Germany, ref. A0830). Membranes were next incubated in TBS containing 0.1% Tween, 5% milk and 
primary antibody (GLT-1; Alpha Diagnostic International, ref. GLT11-A, RRID: AB_1622410, 1:500 or HTT, 
Sicgen, ref. AB0080-200, RRID: AB_2333150, 1:1000), at 4°C during 48h (GLT-1) or 12h (HTT). Membranes were 
washed three times with TBS 0.1% Tween, and incubated 2h at RT in TBS containing 0.1% Tween, 5% milk and 
secondary antibody (HRP-donkey anti-rabbit; GE Healthcare, ref. NA9340, RRID: AB_772191, 1:7000 or HRP-
donkey anti-goat, Santa Cruz, Heildeberg, Germany, ref. sc-2056, RRID: AB_631730, 1:10.000). Blots were next 
washed three times in TBS 0.1% Tween and processed using Western Bright Sirius ECL kit (Advansta, Menlo Park, 
USA, ref. K12043-D20), according to kit recommendations. Chemiluminescence detection was performed with the 
ChemiDoc
TM
 XRS System (BIO-RAD, Cressier, Switzerland, ref. 170-8070). For GLT-1 blots total protein content 
assay was performed with the Pierce Reversible Protein Stain kit (ThermoFicher Scientific, Waltham, USA, ref. 
24580) according to kit recommendations. Both labeling were quantified with the ImageLab 3.0 (BIO-RAD, 
Cressier, Switzerland, software available on: http://www.bio-rad.com/en-us/product/image-lab-software), and GLT1 
protein level was normalized to the total protein content.  
Statistical Analysis:  
Statistical analyses were performed with Statistica 10 Statsoft (DELL, software available on: 
http://www.statsoft.com/Products/STATISTICA-Features/Version-10). Student’s t tests were performed when only 
two groups were compared otherwise Factorial ANOVA was applied. A repeated measure ANOVA was used for 
Rotarod Accelerated Test. Post-hoc LSD Fisher tests were applied after ANOVA if significant. P value < 0.05 was 
considered as significant. Pearson correlations were performed in Statistica 10 Statsoft, behavioral scores of clasping, 
thigmotaxis, and motor activity in the Open Field were inverted, and p value correction by FDR estimation was 
performed with R 3.1.2 and stats package (http://www.R-project.org), according to Benjamini and Hochberg method 
(Benjamini and Hochberg, 1995). Figures were realized with Inkscape 0.91 (software available on: 
https://inkscape.org/fr/), graphics were performed in R 3.1.2 with ggplot2 and grid packages (Wickham, 2009). 
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Figure S1: Analysis of transgene expression in the basal ganglia circuit after injection of AAV2/5 in 
the mouse striatum. 
 
(A) Mosaic acquisitions of mouse striatum 3 weeks after injection of CBA-eGFP in two sites per 
hemispheres (5E10
7
 viral genome/site). Immunohistochemistry against eGFP was performed. 
Expression of eGFP was detected in large part of the striatum, both in medio-lateral and anterior-
posterior axes. Brain 3D representation was exported from Brain Explorer 2 software (Allen Institute 
for Brain Science, Seattle (WA), available from: http://human.brain-map.org/static/brainexplorer). 
(B) Pictures of distinct structures of the mouse basal ganglia system three weeks after co-injection of 
CBA-mCherry and Gfa2(B)3-eGFP AAV2/5 in two sites per hemisphere (5E10
7
 viral genomes/sites 
per viral vector). mCherry-positive and eGFP-positive cell were detected in the Caudate-Putamen, the 
Nucleus Accumbens (NAcc), the Lateral Globus Pallidus (LGP), the substantia nigra and the primary 
motor cortex (M1). Scale bar = 100µm. aca = anterior commissure anterior part, ic = internal capsule, 
SNr = substantia nigra pars reticulata, SNc = substantia nigra pars compacta, cc = corpus collosum. To 
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help visualization, acquisition parameters differs between structures due to high heterogeneity in eGFP 
and/or mCherry expression levels. 
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Figure S2: Characterization of mHTT aggregates in the striatum of the three mouse models.  
 
(A) Representative pictures of striatal sections immunolabeled against aggregated HTT (EM48 
antibody), for control mice injected with CBA-HTT171-18Q (left panel), Gfa2(B)3-HTT171-18Q 
(middle panel) or CBA/Gfa2(B)3-HTT171-18Q AAV2/5 (right panel) at 16 weeks post-injection. Scale 
bar = 20µm.  
(B) Confocal acquisitions of eGFP, mHTT aggregates (Sicgen antibody) and either neuronal (NeuN) or 
astrocytic (GFAP) markers, that illustrate the absence of inter-cellular spreading of mHTT-positive 
aggregates 16 weeks after injection of either CBA-HTT171-82Q (upper panels) or Gfa2(B)3-HTT171-
82Q (lower panels) viral vectors. Scale bar = 10µm. 
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Figure S3: Characterization of mHTT aggregates in part of the basal ganglia circuit of the three mouse 
models.  
 
(A) Pictures of distinct basal ganglia structures stained for EM48 in CBA-HTT171-82Q (left panels), 
Gfa2(B)3-HTT171-82Q (middle panels) or CBA/Gfa2(B)3-HTT171-82Q (right panels) mice. Main 
structures are delimited by black dotted lines. NAcc = nucleus accumbens, LGP = lateral globus 
pallidus, SNc = substantia nigra pars compacta, SNr = substantia nigra pars reticulate, Cx M1 = 
primary motor cortex, aca = anterior commissure, anterior part, ic = internal capsule, cc = corpus 
callosum. Scale bar = 20µm. 
(B) Low magnification pictures of the arcuate nucleus of the hypothalamus stained for EM48 16 weeks 
post-injection in CBA-HTT171-82Q mice (left panel), Gfa2(B)3-HTT171-82Q mice (middle panel) or 
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CBA/Gfa2(B)3-HTT171-82Q mice (right panel). Arc = arcuate nucleus of the hypothalamus. Scale bar 
= 200µm. 
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Figure S4: Evaluation of neuronal death in the three mouse models   
 
Confocal mosaic acquisitions of sections immunolabeled for NeuN (left pictures) and GFP (right 
pictures) 16 weeks after injection in CBA-HTT171 mice (left panels), Gfa2(B)3-HTT171 mice (middle 
panels) or CBA/Gfa2(B)3-HTT171 mice (right panels). Mice expressing mutant HTT (82Q) are 
presented in upper panels. Mice with control HTT (18Q) are presented in lower panels. Co-
immunolabeling with eGFP staining was performed to help the visualization of the injection area. 
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Figure S5: Characterization of the astrogliosis at 4 and 16 weeks post-injection.  
 
(A) Low magnification pictures of Gfap immunolabelings of the mouse striatum 4 weeks after injection 
of AAV2/5 expressing CBA-HTT171 (left panels), Gfa2(B)3-HTT171 (middle panels) or 
CBA/Gfa2(B)3-HTT171 (right panels) with mutant (82Q, up panels) or control (18Q, low panels) HTT. 
Scale bar = 50µm. 
(B) Quantification of the total number of Gfap-positive cells per mm2 in the mice striatum 16 weeks 
after injection of CBA/Gfa2(B)3-HTT171-82Q (black bar) or CBA/Gfa2(B)3-HTT171-18Q (gray bar) 
viral vectors. Analysis was performed on 2 pictures/slice, 3 slices/n, n=8-10/group). Data represent 
mean ± SEM. Student’s t test, NS: p. value ≥ 0.05. 
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